Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AR 105

Next Previous
Drug Profile

AR 105

Alternative Names: Aerubumab; Aerucin; AR-105; CM 101 - Aridis Pharmaceuticals; CM101; F 429

Latest Information Update: 09 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kenta Biotech
  • Developer Aridis Pharmaceuticals
  • Class Antibacterials; Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia
  • Discontinued Cystic fibrosis

Most Recent Events

  • 09 Feb 2024 Pipeline push - Updated indication to nosocomial pneumonia as per pipeline mentions hospital and ventilator acquired pneumonia
  • 31 Dec 2020 Aridis Pharmaceuticals in-licenses patents for AR 105 from The Brigham and Women's Hospital
  • 31 Dec 2020 AAR 105 is still in phase II trials for Pneumonia USA, Spain, Poland, Hungary, Greece, Germany, Czech Republic and Belgium (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top